Elevation Pharmaceuticals Receives $30,000,000 Series A Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=bfbf8549-b309-4927-89ab-b9d17c04cff5&Preview=1 -
Date
1/21/2010 -
Company Name
Elevation Pharmaceuticals -
Mailing Address
12671 High Bluff Drive San Diego, CA 92130 -
Company Description
Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. Our founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients’ lives. At Elevation, we have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. We are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders — employees, investors, partners, and patients. -
Website
http://www.elevationpharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$30,000,000 -
Transaction Round
Series A -
Proceeds Purposes
This capital will enable development of our first candidate through mid-stage clinical trials as well as begin development of a pipeline of product candidates targeted at underserved patient subpopulations with respiratory disease. -
M&A Terms
-
Venture Investor
Canaan Partners -
Venture Investor
TPG – Texas Pacific Group Ventures -
Venture Investor
Care Capital -
Venture Investor
Mesa Verde Venture Partners
